Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Down 14.2% in January

Aura Biosciences, Inc. (NASDAQ:AURA) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,210,000 shares, a decline of 14.2% from the January 15th total of 1,410,000 shares. Based on an average daily volume of 179,200 shares, the days-to-cover ratio is currently 6.8 days. Currently, 2.7% of the company’s stock are short sold.

Wall Street Analyst Weigh In

AURA has been the subject of a number of recent analyst reports. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research note on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $23.00.

Aura Biosciences Price Performance

Shares of NASDAQ:AURA traded up $0.01 during trading on Friday, hitting $7.95. The company had a trading volume of 339,620 shares, compared to its average volume of 124,057. Aura Biosciences has a one year low of $6.63 and a one year high of $12.38. The company has a fifty day simple moving average of $8.08 and a two-hundred day simple moving average of $8.79.

Insider Transactions at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the sale, the insider now directly owns 151,693 shares of the company’s stock, valued at $1,419,846.48. The trade was a 7.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,778 shares of company stock worth $240,706 over the last quarter. 5.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its stake in shares of Aura Biosciences by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after acquiring an additional 3,612 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after acquiring an additional 3,972 shares during the last quarter. Wells Fargo & Company MN lifted its stake in shares of Aura Biosciences by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after acquiring an additional 5,930 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aura Biosciences during the 4th quarter worth approximately $87,000. Finally, Barclays PLC lifted its stake in shares of Aura Biosciences by 19.2% during the 4th quarter. Barclays PLC now owns 72,725 shares of the company’s stock worth $598,000 after acquiring an additional 11,715 shares during the last quarter. 96.75% of the stock is owned by institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.